Axa
HRTX icon

Axa’s Heron Therapeutics HRTX Stock Holding History

Axa’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-265,000
Closed -$400K – 1118
2023
Q1 		$400K Sell
265,000
-12,700
-5% -$31.8K ﹤0.01% 991
2022
Q4 		$694K Hold
277,700
– – ﹤0.01% 942
2022
Q3 		$1.17M Buy
+277,700
New +$1.09M ﹤0.01% 838
2018
Q4 		– Sell
-27,900
Closed -$883K – 1327
2018
Q3 		$883K Buy
27,900
+3,100
+13% +$115K ﹤0.01% 1059
2018
Q2 		$963K Buy
+24,800
New +$790K ﹤0.01% 1012
2016
Q2 		– Sell
-43,820
Closed -$832K – 1386
2016
Q1 		$832K Sell
43,820
-13,840
-24% -$273K ﹤0.01% 906
2015
Q4 		$1.54M Buy
+57,660
New +$1.54M 0.01% 828

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Axa's HRTX Position: Q2 2023 in Review

Axa sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 265,000 shares — an estimated $400K sold.

Axa first reported a position in HRTX in Q4 2015 and held it in 7 quarters. The position peaked at $1.54M in Q4 2015. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

  • Axa reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Axa sold 265,000 Heron Therapeutics shares in Q2 2023, an estimated $400K.
  • Axa first reported a position in Heron Therapeutics in Q4 2015 and held it in 7 quarters.
  • Axa's Heron Therapeutics position peaked at $1.54M in Q4 2015.
  • 149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Axa's 13F filing for Q2 2023, filed 14 Aug 2023.